Mineralocorticoid receptor antagonists in dialysis patients after ACHIEVE and ALCHEMIST: updated systematic review and meta-analysis of 14 randomized trials
Ren Fail. 2026 Dec;48(1):2656561. doi: 10.1080/0886022X.2026.2656561. Epub 2026 Apr 29.ABSTRACTEnd-stage kidney disease (ESKD) patients receiving dialysis bear a heavy burden of cardiovascular disease (CVD), the leading cause of mortality. Mineralocorticoid receptor antagonists (MRAs) have cardiovas

